FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity
August 02, 2022 19:15 ET
|
Coherus BioSciences, Inc.
- CIMERLI™ is Coherus’ third FDA-approved product and the first of four new product launches planned by the end of 2023 - - First CIMERLI™ product sales expected in October 2022 - - COLUMBUS AMD...
Coherus BioSciences Announces New Employment Inducement Grants
August 01, 2022 23:15 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 1, 2022, the compensation...
Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022
July 28, 2022 16:01 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after...
Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
July 06, 2022 08:00 ET
|
Coherus BioSciences, Inc.
- FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will be the first and only immuno-oncology agent for NPC in U.S., if approved - REDWOOD CITY,...
Coherus BioSciences Announces New Employment Inducement Grants
June 22, 2022 16:30 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 16, 2022, the compensation committee...
Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors
May 11, 2022 18:00 ET
|
Coherus BioSciences, Inc.
- Dr. O’Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute’s efforts to advance cancer immunotherapies - REDWOOD CITY, Calif., May ...
Coherus BioSciences Management to Present at Upcoming Investor Conferences
May 10, 2022 08:45 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences...
Coherus BioSciences Reports First Quarter 2022 Results
May 05, 2022 16:01 ET
|
Coherus BioSciences, Inc.
– CIMERLI™ BLA review progressing toward August 2022 action date –– Toripalimab BLA resubmission expected by mid-summer –– UDENYCA® delivers 1st quarter 2022 net sales of $60.1 million –– 2022 R&D...
Coherus BioSciences Appoints Charlie Newton to Board of Directors
May 05, 2022 08:31 ET
|
Coherus BioSciences, Inc.
- Biotechnology Chief Financial Officer and highly regarded former healthcare investment banker brings decades of industry experience to Coherus’ immuno-oncology strategy execution - REDWOOD CITY,...
Coherus BioSciences Announces New Employment Inducement Grants
May 03, 2022 21:45 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective April 27, 2022, the compensation...